Sangamo Therapeutics (SGMO)
0.18
0.00 (0.00%)
Upcoming Events
Latest Headlines
Sangamo Therapeutics explores strategic alternatives with Raymond James
June 8, 2026 8:06 AM - StreetInsider
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
June 8, 2026 8:05 AM - Globe NewsWire
Form 4 SANGAMO THERAPEUTICS, For: May 25 Filed by: Jain Nikunj
May 27, 2026 7:30 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: May 25 Filed by: Dubois-Stringfellow Nathalie
May 27, 2026 7:30 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: May 25 Filed by: Davis Gregory D
May 27, 2026 7:30 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: May 25 Filed by: Willoughby Scott B.
May 27, 2026 7:30 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: May 25 Filed by: Macrae Sandy
May 27, 2026 7:30 PM - SEC Filing
Sangamo BioSciences (SGMO) PT Lowered to $5 at H.C. Wainwright
May 26, 2026 11:44 AM - StreetInsider
Form SCHEDULE 13G SANGAMO THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:27 AM - SEC Filing
Form 10-Q SANGAMO THERAPEUTICS, For: Mar 31
May 14, 2026 4:05 PM - SEC Filing
Form 8-K SANGAMO THERAPEUTICS, For: May 14
May 14, 2026 4:03 PM - SEC Filing
Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c
May 14, 2026 4:03 PM - StreetInsider
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
May 14, 2026 4:01 PM - Globe NewsWire
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
May 11, 2026 4:05 PM - Globe NewsWire
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
April 30, 2026 8:05 AM - Globe NewsWire
Form 10-K/A SANGAMO THERAPEUTICS, For: Dec 31
April 30, 2026 6:09 AM - SEC Filing
Form 8-K SANGAMO THERAPEUTICS, For: Apr 28
April 29, 2026 8:37 AM - SEC Filing
Sangamo Therapeutics moves to OTCQB after Nasdaq delisting notice
April 29, 2026 8:05 AM - StreetInsider
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
April 29, 2026 8:05 AM - Globe NewsWire
Form 4 SANGAMO THERAPEUTICS, For: Apr 22 Filed by: Davis Gregory D
April 23, 2026 7:23 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: Apr 21 Filed by: Dubois-Stringfellow Nathalie
April 23, 2026 7:23 PM - SEC Filing
Form 144 SANGAMO THERAPEUTICS, Filed by: Davis Gregory D
April 22, 2026 4:01 PM - SEC Filing
Form 144 SANGAMO THERAPEUTICS, Filed by: Dubois-Stringfellow Nathalie
April 6, 2026 7:08 AM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: Apr 01 Filed by: Dubois-Stringfellow Nathalie
April 3, 2026 4:16 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: Apr 01 Filed by: Macrae Sandy
April 3, 2026 4:16 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: Apr 01 Filed by: Jain Nikunj
April 3, 2026 4:15 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: Apr 01 Filed by: Davis Gregory D
April 3, 2026 4:15 PM - SEC Filing
Form 4 SANGAMO THERAPEUTICS, For: Apr 01 Filed by: Willoughby Scott B.
April 3, 2026 4:15 PM - SEC Filing
Form 10-K SANGAMO THERAPEUTICS, For: Dec 31
March 30, 2026 5:37 PM - SEC Filing
Form 8-K SANGAMO THERAPEUTICS, For: Mar 30
March 30, 2026 5:30 PM - SEC Filing
Sangamo Therapeutics (SGMO) Misses Q4 EPS by 10c
March 30, 2026 4:52 PM - StreetInsider
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
March 30, 2026 4:01 PM - Globe NewsWire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
March 19, 2026 4:03 PM - Globe NewsWire
Full Article List
